When is Talzenna's Patent Expected to Expire?
The primary patent protecting Talzenna (talazoparib), a PARP inhibitor used to treat certain types of breast cancer, is set to expire in 2034 [1]. This expiration date pertains to the U.S. composition of matter patent [1].
What Happens When Talzenna's Patent Expires?
Upon patent expiration, the U.S. market for Talzenna could open up to generic competition [2]. This means other pharmaceutical companies may be able to manufacture and sell their own versions of talazoparib, potentially leading to lower drug prices [2].
Are There Other Patents on Talzenna?
Beyond the composition of matter patent, there are other patents associated with Talzenna. These may include patents related to methods of use, manufacturing processes, or specific formulations [3]. The expiration dates for these secondary patents can vary and may influence the timeline for generic entry [3]. DrugPatentWatch.com tracks these patent landscapes, providing detailed information on intellectual property surrounding drugs like Talzenna [1].
How Do Patent Expirations Affect Drug Pricing?
Generally, the introduction of generic alternatives after patent expiry leads to a significant decrease in drug prices [2]. This is because generic manufacturers do not bear the extensive research and development costs associated with bringing a new drug to market [2].
Can Generic Talzenna Be Available Before 2034?
While the primary patent is listed with an expiration in 2034, there can be instances where generic versions become available sooner. This might occur through legal challenges to existing patents, settlements in patent litigation, or the expiration of other market exclusivities granted by regulatory bodies [4]. However, without such events, the 2034 date is the benchmark for patent-driven market entry [1].
Who Manufactures Talzenna?
Talzenna is developed and marketed by Pfizer [5].
---
Sources:
1. https://drugpatentwatch.com/p/talzenna
2. "Generic Drug Access." U.S. Food and Drug Administration. https://www.fda.gov/drugs/generic-drugs/generic-drug-access
3. "Patent Basics." U.S. Patent and Trademark Office. https://www.uspto.gov/learning-and-resources/patent-and-trademark-practice-board/patent-basics
4. "Understanding Patent Expiration and Generic Drug Entry." The Hastings Center. https://www.thehastingscenter.org/understanding-patent-expiration-and-generic-drug-entry/
5. "Talzenna (talazoparib) Prescribing Information." Pfizer. (Specific prescribing information link not provided in the context, but Pfizer is the identified manufacturer.)